Analyse court terme - NOVAVAX : La tendance de fond est clairement orientée à la baisse.
La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 1,45 $ prochainement.Le prochain objectif est à 1,06 $, puis 0,96 $. Le franchissement de 1,45 $ remettrait en cause la suite de la baisse.
Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. Using recombinant nanoparticle vaccine technology, the company produces vaccine candidates to respond to disease threats. The company's product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus and the Ebola virus, and preclinical programs for other infectious disease vaccine candidates. The company is also developing immune stimulating saponin-based adjuvants through its subsidiary, Novavax AB.
DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.